Why is launching a drug in Europe different from launching in the US?

What’s Inside the Q&A:

• Regulatory Structure Insights – Key differences between FDA’s unified approach and Europe’s multiple authorization pathways.
• Multi-country Considerations – Why harmonization challenges across 27 EU nations require different strategic thinking.
• Review Process Understanding – How EMA’s unique “clock-stop” review cycles affect your preparation and timeline planning.
• Post-Approval Realities – Critical differences between US and EU market access that impact your commercialization planning.